FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892669486> ?p ?o ?g. }

• W2892669486 endingPage "1063" @default.
• W2892669486 startingPage "1057" @default.
• W2892669486 abstract "Abstract OBJECTIVE To assess pharmacokinetics of tranexamic acid (TXA) in dogs and assess antifibrinolytic properties of TXA in canine blood by use of a thromboelastography-based in vitro model of hyperfibrinolysis. ANIMALS 6 healthy adult dogs. PROCEDURES Dogs received each of 4 TXA treatments (10 mg/kg, IV; 20 mg/kg, IV; approx 15 mg/kg, PO; and approx 20 mg/kg, PO) in a randomized crossover-design study. Blood samples were collected at baseline (time 0; immediately prior to drug administration) and predetermined time points afterward for pharmacokinetic analysis and pharmacodynamic (thromboelastography) analysis by use of an in vitro hyperfibrinolysis model. RESULTS Maximum amplitude (MA [representing maximum clot strength]) significantly increased from baseline at all time points for all treatments. The MA was lower at 360 minutes for the 10-mg/kg IV treatment than for other treatments. Percentage of clot lysis 30 minutes after MA was detected was significantly decreased from baseline at all time points for all treatments; at 360 minutes, this value was higher for the 10-mg/kg IV treatment than for other treatments and higher for the 20-mg/kg IV treatment than for the 20-mg/kg PO treatment. Maximum plasma TXA concentrations were dose dependent. At 20 mg/kg, IV, plasma TXA concentrations briefly exceeded concentrations suggested for complete inhibition of fibrinolysis. Oral drug administration resulted in a later peak antifibrinolytic effect than did IV administration. CONCLUSIONS AND CLINICAL RELEVANCE Administration of TXA improved clot strength and decreased fibrinolysis in blood samples from healthy dogs in an in vitro hyperfibrinolysis model. Further research is needed to determine clinical effects of TXA in dogs with hyperfibrinolysis." @default.
• W2892669486 created "2018-10-05" @default.
• W2892669486 creator A5014785147 @default.
• W2892669486 creator A5021121986 @default.
• W2892669486 creator A5026553025 @default.
• W2892669486 creator A5026679972 @default.
• W2892669486 creator A5056599841 @default.
• W2892669486 creator A5074079824 @default.
• W2892669486 date "2018-10-01" @default.
• W2892669486 modified "2023-10-11" @default.
• W2892669486 title "Pharmacokinetics of tranexamic acid in healthy dogs and assessment of its antifibrinolytic properties in canine blood" @default.
• W2892669486 cites W1484214690 @default.
• W2892669486 cites W1816621823 @default.
• W2892669486 cites W1867016089 @default.
• W2892669486 cites W1879660458 @default.
• W2892669486 cites W1964578279 @default.
• W2892669486 cites W1977716630 @default.
• W2892669486 cites W1992034786 @default.
• W2892669486 cites W2001022087 @default.
• W2892669486 cites W2064734780 @default.
• W2892669486 cites W2074630994 @default.
• W2892669486 cites W2088977315 @default.
• W2892669486 cites W2107732057 @default.
• W2892669486 cites W2139431842 @default.
• W2892669486 cites W2150954466 @default.
• W2892669486 cites W2161643754 @default.
• W2892669486 cites W2162249417 @default.
• W2892669486 cites W2165264387 @default.
• W2892669486 cites W2324437595 @default.
• W2892669486 cites W2546501851 @default.
• W2892669486 doi "https://doi.org/10.2460/ajvr.79.10.1057" @default.
• W2892669486 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30256146" @default.
• W2892669486 hasPublicationYear "2018" @default.
• W2892669486 type Work @default.
• W2892669486 sameAs 2892669486 @default.
• W2892669486 citedByCount "24" @default.
• W2892669486 countsByYear W28926694862019 @default.
• W2892669486 countsByYear W28926694862020 @default.
• W2892669486 countsByYear W28926694862021 @default.
• W2892669486 countsByYear W28926694862022 @default.
• W2892669486 countsByYear W28926694862023 @default.
• W2892669486 crossrefType "journal-article" @default.
• W2892669486 hasAuthorship W2892669486A5014785147 @default.
• W2892669486 hasAuthorship W2892669486A5021121986 @default.
• W2892669486 hasAuthorship W2892669486A5026553025 @default.
• W2892669486 hasAuthorship W2892669486A5026679972 @default.
• W2892669486 hasAuthorship W2892669486A5056599841 @default.
• W2892669486 hasAuthorship W2892669486A5074079824 @default.
• W2892669486 hasConcept C111113717 @default.
• W2892669486 hasConcept C112705442 @default.
• W2892669486 hasConcept C126322002 @default.
• W2892669486 hasConcept C141071460 @default.
• W2892669486 hasConcept C142724271 @default.
• W2892669486 hasConcept C1621761 @default.
• W2892669486 hasConcept C204787440 @default.
• W2892669486 hasConcept C22979827 @default.
• W2892669486 hasConcept C26809991 @default.
• W2892669486 hasConcept C27081682 @default.
• W2892669486 hasConcept C2776825266 @default.
• W2892669486 hasConcept C2777664302 @default.
• W2892669486 hasConcept C2778382381 @default.
• W2892669486 hasConcept C2779637338 @default.
• W2892669486 hasConcept C2781219028 @default.
• W2892669486 hasConcept C2781436528 @default.
• W2892669486 hasConcept C2910686401 @default.
• W2892669486 hasConcept C2991743468 @default.
• W2892669486 hasConcept C42219234 @default.
• W2892669486 hasConcept C71924100 @default.
• W2892669486 hasConcept C87813604 @default.
• W2892669486 hasConcept C98274493 @default.
• W2892669486 hasConceptScore W2892669486C111113717 @default.
• W2892669486 hasConceptScore W2892669486C112705442 @default.
• W2892669486 hasConceptScore W2892669486C126322002 @default.
• W2892669486 hasConceptScore W2892669486C141071460 @default.
• W2892669486 hasConceptScore W2892669486C142724271 @default.
• W2892669486 hasConceptScore W2892669486C1621761 @default.
• W2892669486 hasConceptScore W2892669486C204787440 @default.
• W2892669486 hasConceptScore W2892669486C22979827 @default.
• W2892669486 hasConceptScore W2892669486C26809991 @default.
• W2892669486 hasConceptScore W2892669486C27081682 @default.
• W2892669486 hasConceptScore W2892669486C2776825266 @default.
• W2892669486 hasConceptScore W2892669486C2777664302 @default.
• W2892669486 hasConceptScore W2892669486C2778382381 @default.
• W2892669486 hasConceptScore W2892669486C2779637338 @default.
• W2892669486 hasConceptScore W2892669486C2781219028 @default.
• W2892669486 hasConceptScore W2892669486C2781436528 @default.
• W2892669486 hasConceptScore W2892669486C2910686401 @default.
• W2892669486 hasConceptScore W2892669486C2991743468 @default.
• W2892669486 hasConceptScore W2892669486C42219234 @default.
• W2892669486 hasConceptScore W2892669486C71924100 @default.
• W2892669486 hasConceptScore W2892669486C87813604 @default.
• W2892669486 hasConceptScore W2892669486C98274493 @default.
• W2892669486 hasIssue "10" @default.
• W2892669486 hasLocation W28926694861 @default.
• W2892669486 hasLocation W28926694862 @default.
• W2892669486 hasOpenAccess W2892669486 @default.
• W2892669486 hasPrimaryLocation W28926694861 @default.
• W2892669486 hasRelatedWork W1979241362 @default.

• next